Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $33.37.

NTLA has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their target price on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Citigroup decreased their target price on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Truist Financial lowered their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research report on Monday, April 21st. Finally, Wedbush restated a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Voya Investment Management LLC raised its position in shares of Intellia Therapeutics by 621.5% during the 1st quarter. Voya Investment Management LLC now owns 208,009 shares of the company's stock valued at $1,479,000 after acquiring an additional 179,180 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock valued at $3,709,000 after purchasing an additional 38,521 shares during the period. Woodline Partners LP bought a new stake in Intellia Therapeutics in the first quarter valued at approximately $171,000. Arete Wealth Advisors LLC boosted its position in shares of Intellia Therapeutics by 21.8% during the first quarter. Arete Wealth Advisors LLC now owns 12,512 shares of the company's stock worth $89,000 after purchasing an additional 2,240 shares in the last quarter. Finally, Granahan Investment Management LLC boosted its position in shares of Intellia Therapeutics by 55.3% during the first quarter. Granahan Investment Management LLC now owns 475,946 shares of the company's stock worth $3,384,000 after purchasing an additional 169,436 shares in the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA traded down $0.14 during mid-day trading on Friday, reaching $9.42. 366,919 shares of the company traded hands, compared to its average volume of 3,873,938. The company's fifty day moving average is $8.56 and its two-hundred day moving average is $9.43. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The stock has a market cap of $975.41 million, a PE ratio of -1.80 and a beta of 2.15.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter last year, the company posted ($1.12) earnings per share. The company's revenue for the quarter was down 42.6% compared to the same quarter last year. Research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.